Torrent Pharmaceuticals share news, announcements and annual reports
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,613.40up ₹33.40 (0.73%)BSE ₹4,635.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹4,580.00.
30 Oct: open ₹4,560.00, high ₹4,672.00, low ₹4,532.00
52-week range of traded prices to 30 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,75,479 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 82.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.82%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,36,64564.6% delivered
Torrent Pharmaceuticals disputes and clarifications
15 filed, newest first.
Feb 2025
17 Feb · Legal
Nov 2024
28 Nov · Legal
Oct 2022
May 2019
23 May · Legal
Exchange has sought clarification from Torrent Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.
Aug 2017
1 Aug · Legal
Exchange has sought clarification from Torrent Pharmaceuticals Limited with respect to announcement dated 31-Jul-2017, regarding appointment of B S R & Co. LLP, Chartered Accountant.On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
May 2017
12 May · Legal
Exchange has sought clarification from the Company with respect to news item captioned Torrent Pharma Gets Four U.S. FDA Observations For Indrad Plant . In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2017
10 Apr · Legal
Exchange has sought clarification from the Company with respect to recent news item captioned "Torrent Close to Buying Novartis Business". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2015
15 Apr · Legal
Exchange has sought clarification from Torrent Pharmaceuticals Limited with respect to recent news item captioned "Torrent eyes Encore derma biz for Rs. 350cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
26 Dec · Legal
Exchange has sought clarification from Torrent Pharmaceuticals Limited with respect to recent news item captioned "Torrent Pharma in pact with Reliance Life to sell biosimilars". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Aug 2014